Skip to main content
Premium Trial:

Request an Annual Quote

Cellumen, NCTR Collaborate on Liver Toxicity Testing

NEW YORK (GenomeWeb News) – Cellumen said today that it has entered into a research collaboration with the National Center for Toxicological Research, part of the US Food and Drug Administration, to test known liver toxicity drugs.
 
Cellumen will use its CellCiphr cell-based assay to create profiles of blinded samples of these compounds from failed and marketed drugs, and the NCTR will incorporate information about these drugs into a liver toxicity knowledge database.
 
The company said that its profiling technology can be used by drug companies to identify “compounds with high human toxic liabilities,” allowing drug companies to take actions or to measure the risk of certain compounds.
 
Cellumen also said it plans to use the profiling and safety data from the collaboration to continue to develop the CellCiphr database, cell panels, and informatics tools.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.